Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

This activity was originally presented live at Asembia's AXS25 Summit in Las Vegas, Nevada on April 28, 2025.

Program Description
Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a significant clinical and economic burden, characterized by substantial health care resource utilization, reduced quality of life due to bothersome symptoms and common comorbidities, and ongoing challenges in optimizing patient management despite current treatments. Limitations of current strategies, including surgery, and the risks associated with systemic corticosteroids highlight a critical unmet need for more targeted therapies. Biologics are increasingly being used in CRSwNP to improve patient outcomes and reduce disease burden. Despite being reserved for treatment after nasal corticosteroids and surgery failure, recent studies support their use in patients with CRSwNP and various comorbidities. Specialty pharmacists play a crucial role in this evolving landscape by reviewing health care utilization, reducing direct and indirect costs, ensuring access through patient support programs, and improving patient quality of life. This session will examine opportunities for specialty pharmacists to engage patients in their care and maximize benefits of biologic therapies for CRSwNP. In addition to the clinical data and guidelines surrounding approved and emerging biologics, this session will equip pharmacists with practical skills necessary for early patient identification, seamless biologic initiation, thorough counseling, adherence monitoring, and proactive management of this complex condition to optimize outcomes for patients and reduce the overall impact of CRSwNP.

Target Audience: Managed care and specialty pharmacists

Type of Activity: Application
Release date: May 6, 2025
Expiration date: May 6, 2026
Learner level: Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain how biologic therapy addresses immune dysregulation and inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP)
• Analyze current gaps in management of CRSwNP and the role of approved and emerging biologic therapies
• Identify counseling pearls on biologic utilization in CRSwNP, including administration, selection, and access